Invasive Ductal Carcinoma

Invasive ductal carcinoma begins in the epithelial cells that line the breast's milk ducts — the channels that carry milk to the nipple. When cells in those ducts undergo malignant changes and break through the duct wall into the surrounding breast tissue, the cancer is classified as invasive ductal carcinoma. It is the most common breast cancer type, representing roughly 70 to 80 percent of all invasive breast cancer diagnoses.

IDC is not one uniform disease. Its behavior and the treatments used to fight it depend heavily on a set of biological characteristics your pathologist will measure from a biopsy sample. These include the cancer's grade (how abnormal the cells look and how fast they are dividing), its hormone receptor status (whether the cancer cells have estrogen or progesterone receptors that fuel their growth), and its HER2 status (whether the cancer overproduces a growth-promoting protein called HER2). A cancer that tests positive for hormone receptors responds to hormonal therapies; a HER2-positive cancer responds to targeted drugs like trastuzumab. Triple-negative IDC, which lacks all three receptors, requires a different treatment approach.

Once IDC is diagnosed, staging — which accounts for tumor size, lymph node involvement, and presence of distant metastasis — determines how advanced the cancer is and guides the overall treatment plan. For many women with early-stage IDC, the prognosis with appropriate treatment is very good. Treatment typically involves surgery plus one or more systemic therapies (chemotherapy, hormone therapy, targeted therapy) and often radiation, tailored to the specific tumor profile.

If you have been diagnosed with IDC, it helps to know that it is the most common and most studied form of breast cancer, which means there is a substantial body of research guiding its treatment. That also means your care team has extensive experience with it and a wide range of therapeutic tools available.

Understanding your tumor's receptor profile — hormone receptor status and HER2 status — is one of the most important pieces of information you can have, because it directly determines which treatments are most likely to work for your specific cancer. Asking your oncologist to explain these results in plain language, and what they mean for your treatment options, is a good place to start. Many women with IDC have multiple treatment paths to consider, and a multidisciplinary team — including a breast surgeon, medical oncologist, and radiation oncologist — can help you weigh them based on your tumor characteristics, your overall health, and your personal priorities.